Transcriptomics Market expected to reach $33.68 Billion by 2031

The transcriptomics market is an emerging market with huge growth potential. Recent technological advancements are facilitating the adoption of the technology at a rapid pace. Transcriptomics offers the ability to isolate a single cell with specific phenotypes from a heterogeneous mixture, along with gene expression analysis and protein expression analysis. The unique feature of transcriptomics technology to integrate the data from various molecules and from different cells to study cell-to-cell differentiation enables the study of mechanisms that are visible at a transcriptomic level.

The growth in this market is expected to be driven by the decrease in the cost of sequencing, the global increase in the application of next-generation sequencing and RNA sequencing in transcriptomics, and the advancement of products launches. The growth of other technologies, such as in-situ hybridization, can be attributed to the increased clinical research to understand the involvement of molecular pathology in the diagnosis and prognosis of genetic disorders. Based on region, North America holds the largest share in the market, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. However, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period 2021-2031.

The healthcare experts have found the transcriptomics market to be one of the stable markets, and the global market is predicted to grow at a CAGR of 20.11% during the forecast period 2021-2031.

Key Questions Answered in this Report:

•   How is next-generation sequencing technology affecting the transcriptomics market?
•   What are the major market drivers, challenges, and opportunities in the global transcriptomics market?
•   What are the underlying structures resulting in the emerging trends within the global transcriptomics market?
•   How is the COVID-19 pandemic impacting the global transcriptomics market landscape?
•   What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?
•   What are the key regulatory implications in developed and developing regions pertaining to transcriptomics?
•   What are the potential entry barriers expected to be faced by the companies willing to enter a particular region for the development of transcriptomics?
•   How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment? Following are the segments:
o   Product (instruments, consumables, and software)
o   Technology (next-generation sequencing, polymerase chain reaction, microarray, in-situ hybridization, and other technologies)
o   Application (drug discovery and development, diagnostics, cell biology, single cell analysis, gene expression, and other applications)
o   End User (academic and research institutions, biotechnology and biopharmaceutical companies, and other end users)
o   Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
•   What are the growth opportunities for the companies in the region of their operation?
•   What are the major applications for the companies in the region of their operation?
•   Who are the leading players with significant offerings in the global transcriptomics market?
•   Which companies are anticipated to be highly disruptive in the future, and why?
•   What are the current unmet needs that are being faced in the global transcriptomics market?

Request a Sample - https://bisresearch.com/requestsample?id=1197&type=download

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing microbiome therapeutics market is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...

Ligase Market Opportunities, Strategies, Share, Segmentation, In-depth Analysis 2032

The global ligase market is progressing rapidly with a significant increase in the research and development activities pertaining to a wide range of ligase product for disease detection, accentuating their criticality in healthcare. Ligase enzyme has a critical role in the molecular diagnostics approach, as it ensures the safe and effective application of targeted therapeutics. Most of the players in the global ligase market offer products encompassing the ligation kits and enzymes. The global ligase market is projected to reach $651.4 million by 2032 from $371.2 million in 2021, at a CAGR of 5.29% during the forecast period 2022-2032. The growth in the global ligase market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases on a global level, rising awareness of enzyme based diagnostic testing and significant number of funding for executing research and development. Impact Several techniques are employed in ...

PD-1/PDL-1 Inhibitor Market Growth Prospects, Emerging Trends and Forecast to 2032

PD-1/PDL-1 inhibitors are immune-therapeutic agents used in the treatment of various cancer indications, mostly in the advanced stages. PD-1/PDL-1 inhibitors are monoclonal antibodies majorly of IgG1 and IgG4 types to be administered to patients via injection The current market already has seven approved products in the U.S. and a large number of research activities are currently undergoing in this segment generating interest of commercial as well as academic research institutions. In the current period of precision medicine and providing targeted treatment, identification of target patient has become very important as well as complicated. With the emergence of diagnostic test identifying predictive biomarkers, the selection and administration of targeted treatment has become comparativlely conveninent and efficient. PD-1/PDL-1 inhibitors market are majorly indicated for the treatment of advanced cases of different cancer indications. The PD-1/PDL-1 inibitor treatment has ...

Market Research Reports

Search This Blog